Results 21 to 30 of about 13,238 (216)
Reactogenicity in PLWH.
, 2022 Reactogenicity in PLWH.Wouter F. W. Bierman (4164670), Fanny N. Lauw (14019253), Marvin A. H. Berrevoets (14019256), Yvonne M. Mueller (8281707), Susanne Bogers (14019232), Kees Brinkman (175845), Jan G. den Hollander (14019235), Adriana J. J. Lammers (14019265), Peter D. Katsikis (7490849), Alicja Gorska (14019229), Judith Branger (14019262), Corine H. GeurtsvanKessel (9515272), Marc van der Valk (8708058), Elisabeth H. Gisolf (14019247), Heidi S. M. Ammerlaan (14019244), Anna H. E. Roukens (14019271), Grigorios Papageorgiou (8341326), Virgil A. S. H. Dalm (6004133), Daryl Geers (14019223), Quirijn de Mast (167198), Marit G. A. van Vonderen (13242695), Casper Rokx (824244), Bart J. A. Rijnders (8842919), Kathryn S. Hensley (14019217), Luc B. S. Gelinck (14019238), Anke H. W. Bruns (14019250), Corine E. Delsing (2806357), Rory D. de Vries (9500161), Robert Soetekouw (14019259), Kim C. E. Sigaloff (8098253), Marlou J. Jongkees (14019220), Selwyn H. Lowe (14019268), Hanka Steggink (14019226), Emile F. Schippers (14019241) +33 morecore +1 more sourceReactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
BMC Infectious Diseases, 2022 Background Due to safety signals after vaccination with COVID-19 vector vaccines, several states recommended to complete the primary immunization series in individuals having received one dose of ChAdOx1 (AstraZeneca) with an mRNA vaccine.Lisette Warkentin, Nikoletta Zeschick, Thomas Kühlein, Philipp Steininger, Klaus Überla, Isabelle Kaiser, Christine Gall, Maria Sebastião, Susann Hueber +8 moredoaj +1 more sourceNeutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2
Vaccines, 2021 This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response.Jorge Hernández-Bello, José Javier Morales-Núñez, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Paulina Balcázar-Félix, Jesús Alberto Gutiérrez-Brito, José Alvaro Lomelí-Nieto, José Francisco Muñoz-Valle +8 moredoaj +1 more sourceImmunogenicity and Reactogenicity of CoronaVac: A Cohort Study
COVID, 2022 The ongoing COVID-19 pandemic remained a major public health concern despite a large-scale deployment of vaccines. One of the vaccines is CoronaVac, an inactivated vaccine. The efficacy of the vaccine was estimated at 50.7–83.5% in clinical trials. However, the real-world efficacy often differed.Sri Masyeni, Edison Johar, Anak Agung Gede Budhitresna, Nyoman Mahardika, Nyoman Ratna Kartika Dewi, I Gde Raka Widiana, Frilasita Aisyah Yudhaputri, Khin Saw Aye Myint +7 moreopenaire +1 more sourceRubella Vaccine – How ‘Reactogenic’ is it?
Journal of International Medical Research, 1986 Girls (231) aged 11—13 years were allocated at random to receive one of two RA27/3 rubella vaccines. A high incidence of minor and self-limiting side-effects were found by intensive follow-up. No difference in reactogenicity could be found between vaccines from the Institut Merieux and Wellcome.G V, Griffin, K A, Bryettopenaire +2 more sourcesHomologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers
Vaccines, 2022 At the start of the SARS-CoV-2 pandemic, healthcare workers had an increased risk of acquiring coronavirus disease (COVID)-19. As tertiary care hospitals are critical for the treatment of severely ill patients, the University Hospital Erlangen offered ...Valentin Niekrens, Jan Esse, Jürgen Held, Carina Sophia Knobloch, Philipp Steininger, Bernd Kunz, Christof Seggewies, Christian Bogdan +7 moredoaj +1 more sourceTyphoid VI: A Less Reactogenic Vaccine
Journal of International Medical Research, 1992 A typhoid vaccine derived from the purified Vi capsular polysaccharide (CPS) antigen of Salmonella typhi was compared with a heat-killed whole-cell typhoid vaccine in 637 healthy male volunteers. The individuals were placed in three groups: group 1 received two doses of heat-killed whole-cell typhoid vaccine, at an interval of 28 days; group 2 received N S, Cumberland, J, St Clair Roberts, W S, Arnold, R K, Patel, C H, Bowker +4 moreopenaire +2 more sourcesImmunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
Human Vaccines & Immunotherapeutics, 2023 We conducted a dose-finding phase 2 study of the HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) in two cohorts of children, 6–≤12 months and 1–≤4 years of age (N = 120 per cohort), in Panama and Colombia (ClinicalTrials.gov ...Pio López, Eduardo López-Medina, Xavier Sáez-Llorens, Rodrigo deAntonio, Taisei Masuda, Paul M. Mendelman, James Sherwood, Frank Baehner, Astrid Borkowski +8 moredoaj +1 more sourceReactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
Vaccines, 2021 Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as Alborz Rahmani, Guglielmo Dini, Andrea Orsi, Laura Sticchi, Bianca Bruzzone, Alfredo Montecucco, Luca Pellegrini, Alessia Manca, Alexander Domnich, Angela Battistini, Bruno Kusznir Vitturi, Sonia Zacconi, Nicoletta Debarbieri, Giancarlo Icardi, Paolo Durando +14 moredoaj +1 more sourceSafety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
Human Vaccines & Immunotherapeutics, 2023 As global supply is still inadequate to address the worldwide requirements for HPV vaccines, we assessed the safety and immunogenicity of a new bivalent HPV16/18 vaccine.Li-Wei Shi, Juan Li, Bang-Wei Yu, Li-Rong Huang, Ke Li, Min Ji, Ling-Yun Zhou, Lin Yuan, Shu-Yuan Yang, Jing-Jing Chen, Ling Wang, Zhi-Wei Jiang, Rong-Cheng Li, Yan-Ping Li, Jie-Lai Xia, Zhao-Jun Mo, Chang-Gui Li +16 moredoaj +1 more source